Literature DB >> 23117088

Late onset vascular dysfunction in the R6/1 model of Huntington's disease.

Awahan Rahman1, Mari Ekman, Yulia Shakirova, Kristina E Andersson, Matthias Mörgelin, Jonas S Erjefält, Patrik Brundin, Jia-Yi Li, Karl Swärd.   

Abstract

Huntington's disease is a neurodegenerative disorder that also gives raise to widespread changes in peripheral organs and tissues. We tested the hypothesis that vascular dysfunction may occur in Huntington's disease by studying R6/1 mice which express exon 1 of the mutant huntingtin gene. We assessed arterial function in R6/1 and wild type (WT) mice using myography. Arterial contractility was largely unaltered in R6/1 arteries at 15 and 32 weeks of age. By 40 weeks, contractility was impaired irrespective of which vasoconstrictor we tested. Endothelium-dependent relaxation was not affected, and we observed no changes in arterial geometry or expression of contractile proteins, such as myosin regulatory light chains or smooth muscle α-actin. The frequency of calcium oscillations in R6/1 arterial smooth muscle cells was higher than in WT control tissue, whereas myosin phosphorylation was unaltered. Impairment of force by the mitochondrial inhibitors cyanide and rotenone was less pronounced in R6/1 than in WT arteries and mitochondria were enlarged, in keeping with an effect related to altered mitochondrial function. Our results reveal that arteries in the R6/1 model of Huntington's disease exhibit an age-dependent impairment of contractility and that they depend less on mitochondrial function when they contract.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117088     DOI: 10.1016/j.ejphar.2012.10.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  The small GTPase Rac1 is required for smooth muscle contraction.

Authors:  Awahan Rahman; Benjamin Davis; Cecilia Lövdahl; Veena T Hanumaiah; Robert Feil; Cord Brakebusch; Anders Arner
Journal:  J Physiol       Date:  2013-12-02       Impact factor: 5.182

2.  Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat.

Authors:  Amy C Keller; Leslie A Knaub; Matthew W Miller; Nicholas Birdsey; Dwight J Klemm; Jane E B Reusch
Journal:  J Cardiovasc Pharmacol       Date:  2015-02       Impact factor: 3.105

3.  Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice.

Authors:  A Di Pardo; A Carrizzo; A Damato; S Castaldo; E Amico; L Capocci; M Ambrosio; F Pompeo; C De Sanctis; C C Spinelli; A A Puca; P Remondelli; V Maglione; C Vecchione
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

4.  Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntington's Disease.

Authors:  Andrew D Kane; Youguo Niu; Emilio A Herrera; A Jennifer Morton; Dino A Giussani
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

5.  The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model.

Authors:  Matthew B Veldman; Yesenia Rios-Galdamez; Xiao-Hong Lu; Xiaofeng Gu; Wei Qin; Song Li; X William Yang; Shuo Lin
Journal:  Mol Neurodegener       Date:  2015-12-09       Impact factor: 14.195

6.  Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.

Authors:  Azzam Aladdin; Róbert Király; Pal Boto; Zsolt Regdon; Krisztina Tar
Journal:  Int J Mol Sci       Date:  2019-10-26       Impact factor: 5.923

7.  Altered cerebrovascular response to acute exercise in patients with Huntington's disease.

Authors:  Jessica J Steventon; Hannah Furby; James Ralph; Peter O'Callaghan; Anne E Rosser; Richard G Wise; Monica Busse; Kevin Murphy
Journal:  Brain Commun       Date:  2020-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.